ABSTRACT Reduced liver weight was used to evaluate the potential toxicity in mice of four naturally occurring steroidal glycoalkaloids: a-chaconine and a-solanine, ortomatine and solasonine. Increased liver weight was used to evaluate the three corresponding steroidal aglycones: solanidine, tomatidine, and solasodine and the non-alkaloid adrenal steroid dehydroepiandrosterone (DHEA). Adult female Swiss-Webster mice were fed diets containing test compound concentrations of 0 (control), 1.2, 2.4 or 4.8 mmol/kg diet for 7, 14 or 28 d. Absolute liver weights (LW) and relative liver weights (liver weight/body weight x 100, %LW/BW)were deter mined at autopsy. The %LW/BW was lower than that of the controls in mice fed the potato glycoalkaloid achaconine (-10%, P -~0.05) for 7 d with the 2.4 mmol/ kg diet dose. Under these same conditions, %LW/BW was greater than that of controls in mice fed two aglycones: solanidine (27%, P s 0.001 ) and solasodine (8%, P Â£0.01). Relative liver weight increases induced by the aglycones were determined under time and dose condi tions in which differences in body weight and food con sumption were not significant (2.4 mmol/kg diet for 28 d). under these conditions, the observed %LW/BW in creases relative to the controls were as follows: solani dine (32%, P -.. 0.001), solasodine (22%, P^0.001) and DHEA (16%, P --0.001). Solanidine, solasodine and DHEA were equally potent and were more potent than tomatidine. We also observed that the greater %LW/BW in mice fed 2.4 mmol/kg diet solasodine or solanidine for 14 d declined to near control values if they were fed control diets for another 14 d. The increase in relative Ihrerweight induced by solanidine and solasodine is a reversible adaptive response. These findings and the apparent effects of structure on biological activity should serve as a guide for the removal of the most toxic com pounds from plant foods. The implications of the results for food safety and health are discussed. J. Nutr. 126: 989-999, 1996.
â€¢ glycoalkaloids â€¢food consumption â€¢ hepatomegaly â€¢ mice food safety
Steroidal glycoalkaloids have been found in potatoes (Friedman and Dao 1992) , green tomatoes (Friedman and Levin 1995) and eggplants (Aubert et al. 1989 ). Symptoms of glycoalkaloid toxicity experienced by ani mals and humans include colic pain in the abdomen and stomach, gastroenteritis, diarrhea, vomiting, burn ing sensation about the lips and mouth, hot skin, fever, rapid pulse and headache (van Gelder 1990) . The re ported toxicity of these glycoalkaloids may be due to such adverse effects as 1) anticholinesterase effects on the central nervous system (Roddick 1989) , 2) induc tion of hepatic ornithine decarboxylase, a cell prolifera tion marker enzyme (Caldwell et al. 1991) , and 3) dis ruption of cell membranes affecting the digestive sys tem (Blankemeyer et al. 1992 , Roddick et al. 1992 ). Toxicity does not seem to occur at the genetic level (Friedman and Henika 1992) . One manifestation of these adverse effects may be alkaloid-induced teratogenicity (Keeler et al. 1991 , Renwick et al. 1984 ).
The estimated highest safe level of total glycoalka loids for human consumption is~1 mg/kg body weight, a level that may cause gastrointestinal irrita tion (Slanina 1990 ). The acute toxic dose is estimated to be -1.75 mg/kg body weight (van Gelder 1990) . A lethal dose may be as low as 3-6 mg/kg body weight (Morris and Lee 1984) .
Human consumption of potatoes, an excellent source of carbohydrates and good quality protein, varies by country. For example, the average daily per capita intake in the United States is -167 g (Friedman 1996) ; in the United Kingdom, it is 140 g (Hopkins 1995 ) and in Sweden, 300 g (Slanina 1990 ). The cited amount for the United Kingdom is estimated to contain 14 mg glycoalkaloids. Although the glycoalkaloid concentra tion of most commercial potato varieties is usually be low a suggested guideline of 200 mg/kg fresh potatoes (Maga 1994) , the concentration can increase substan tially on exposure to light and as a result of mechanical injury, including peeling and slicing (Dao and Friedman 1994) . Glycoalkaloids are largely unaffected by food processing, including baking, cooking and frying (Fried man and Dao 1992, Friedman and Levin 1995) . Because the major potato glycoalkaloids, a-chaconine and asolanine, differ in biological potency, may act synergistically and their ratio may vary in different potato cultivars (Friedman and Dao 1992 , care should be exercised in relating doseresponse values of individual glycoalkaloids to total glycoalkaloid concentration of potatoes. New potato varieties may also contain glycoalkaloids of unknown structure and function inherited from their progenitors (Maga 1994) . These considerations suggest a need to reduce steroidal glycoalkaloid levels in the diet, possi bly through suppression of enzymes responsible for their biosynthesis in plants (Stapleton et al. 1991) .
For the purposes of this study, we define the follow ing terms: glycoalkaloidsâ€"naturally occurring, nitro gen-containing plant steroids with a carbohydrate side chain attached to the 3-hydroxy position, e.g., a-cha conine and a-solanine from potatoes, a-tomatine from tomatoes and solasonine from eggplants,-aglyconesâ€" the steroidal parts of the glycoalkaloid lacking the car bohydrate side chain, e.g., solanidine from a-chaconine and a-solanine, tomatidine from a-tomatine and solasodine from solasonine; alkaloidsâ€"glycoalkaloids and aglycones as above. Figure 1 illustrates the structures of the glycoalkaloids, aglycones, and the adrenal steroid, dehydroepiandrosterone (DHEA),3 evaluated in this study. Previously, we have found that dietary consumption of solasodine induces dose-related increases in absolute liver weight (hepatomegaly) and relative liver weight (g liver weight (LW)/g body weight (BW) x 100, %LW/ BW) in male weanling mice treated for 14 d with 0.16% (3.8 mmol/kg diet) solasodine (Friedman 1992) . This hepatomegaly was accompanied by increases in the ac tivities of four liver enzymes: serum alkaline phosphatase, glutamate-oxaloacetate transaminase, glutamatepyruvate transaminase, and Af-demethylase. Histological examination of the tissue from these mice also re vealed a distinctive liver cholangiohepatitis and gastric gland dilation/degeneration.
The purpose of this study is to define possible effects of four glycoalkaloids and three aglycones on food con sumption, body weight, and liver weight changes in â€¢' Abbreviations used: BW, body weight; DHEA, dehydroepian drosterone; LW, liver weight. mice. Because the naturally occurring adrenal steroid dehydroepianderosterone is reported to induce hepato megaly in rats (Beilei et al. 1992) , it was also included in the study. Our specific objectives were as follows: Ã•)to use the dose-response and time-course data to determine relative potencies and structure/function re lationships with regard to liver weight gain in mice and 2) to investigate whether this hepatomegaly is re versible with minimal changes in food consumption and body weight. We also speculate on structural re quirements for activity and propose a possible mecha nism for the observed hepatomegaly.
MATERIALS AND METHODS
Test compounds. Solasodine (mol wt 416), tomati dine (mol wt 417), a-tomatine (mol wt 1034), and DHEA (mol wt 288) were obtained from Sigma Chemi cal (St. Louis, MO). Solanidine (mol wt 397) was ob tained from Atomergic Chemetals (Farmingdale, NY). a-Solanine (mol wt 868) and a-chaconine (mol wt 852) were isolated from potato sprouts (Friedman et al. 1993) . Solasonine (mol wt 884) was purchased from Biosynth AG (Basel, Switzerland). The purity of all compounds was established by HPLC Levin 1992 and 1995) . We did not extract the test com pounds from the diets and analyze them because they are very stable even when subject to cooking and frying (Friedman and Dao 1992) .
Diets. Control mice were fed a pulverized Purina Mouse Chowâ"¢ diet (Purina St. Louis, MO). The pro portion of each test compound is expressed as mmol/ kg diet. In the case of solasodine, for example, 0.2% (2.0 g per kg diet) corresponds to [2 g/416 (mol wt)] X 1000 (mmol/mol) or 4.8 mmol/kg diet. To prepare the master diet, all alkaloids were triturated into a fine powder, weighed into one third of the total diet and mixed for 10 min in a Twin Shell Dry Blender (Pat terson-Kelly Co., East Stroudsberg, PA). The remaining thirds were added and mixed for 10 min. Other diet levels were prepared by splitting the master diet into halves or fourths, adding the difference and mixing for 10 min.
Feeding studies. The study protocol was approved by our Animal Care and Use Committee, which fol lows the guidelines of the National Institutes of Health on the humane use of laboratory animals. Adult 8-wkold female Swiss-Webster mice (26-32 g) were obtained from Simonsen Laboratories (Gilroy, CA). Mice were housed individually in plastic shoebox cages with hard wood shavings for litter. An automatic timer regulated the 12-h light:dark cycle (lights on at 0600). Water was freely available to all groups. All mice were fed 60 g of diet per week in glass food cups with stainless steel retainers. Food consumption was estimated weekly by comparing the remainder in the cup with the original amount. Food consumption was considered to be an estimate because food could be kicked from the cup or contaminated with feces, urine or litter. The mouse feeding studies reported here were based on either dose in mmol/kg diet and/or time of exposure in days. Groups of eight mice were fed control or exper imental diets with doses of 1.2, 2.4 or 4.8 mmol/kg diet of test compound for 7, 14 or 28 d. Doses and times were based on an earlier study with solasodine (Fried man 1992) and limited by toxicity and/or availability of the compounds. The glycoalkaloids, for example, were used at 2.4 mmol/kg diet but only for 7 d due to signifi cant body weight loss. The aglycones were studied over the entire range of doses and times. DHEA was studied over the entire range of doses for 28 d. In the reversibil ity study, mice were fed as follows: Ã•) control diets (14 or 28 d); 2) positive control diets of 2.4 mmol/kg diet solasodine or solanidine (14 or 28 d); and 3) combina tions of either control diets (d 0-14) followed by 2.4 mmol/kg diet solasodine or solanidine diets (d 15-28) or 2.4 mmol/kg diet solasodine or solanidine (d 0-14) followed by control diets (d 15-28) .
Variables assessed in all studies included estimated daily food consumption (g/d) and [g/(kg mouse x d)], changes in body weight (final weight minus initial body weight in g), liver weight (g upon autopsy), and the liver weight to body weight ratio (%LW/BW). To better visualize the magnitude of the differences in the fig ures, all variables are expressed as the "percentage dif ference from controls." 1Values are means Â±SD, n = 8. *P s 0.001, significantly different than the corresponding control, 2-tailed Dunnett Test, bp s 0.05, significantly different than the corresponding control, 2-tailed Dunnett Test, c p Â«0.001, significantly different than the corresponding control, 1-tailed Dunnett Test, dp s 0.05, significantly different than the corresponding control, 1-tailed Dunnett Test.
Statistics. The figures are intended to give a visual overview of the results, whereas tables contain the more detailed information, including results of the tests of significance. Specifically, data were checked for the need for transformation using the Box-Cox ap proach (Box et al. 1978) and, in some cases, transformed to stabilize the variance among treatments. Instances for which transformations were used are denoted by footnotes in the tables. Excluding Table 1 , the follow ing transformations were used: Table 2 , 7 d solasodineâ€"reciprocals for LW and % LW/B W and 28 d solasodineâ€"ranks for BW change, LW, and %LW/BW; Ta ble 3, squared reciprocals for LW and %LW/BW. ANOVA (SAS 1987 ) and Dunnett's test (Dunnett 1955) were used for data in Tables 1, 2 and Table 4 to compare treatment means with their corresponding control means. A variety of tests are required to deal with the different types of mean comparisons. One-and twotailed tests were used to correspond with their associ ated null hypotheses. Two-tailed tests were used for food consumption and body weight variables, whereas one-tailed tests were used for liver weight measure ments. Liver weights were hypothesized to decrease with diets containing glycoalkaloid and to increase with diets containing aglycone (Tables 1-4). Planned contrasts were used for the reversibility results in Table  3 . The 14-d diets containing the test compounds were compared with the corresponding 14-d controls. The 28-d diets, including the switchover diets, were com pared with the corresponding 28-d controls. The Bonferroni adjustment of P' = P/8 was used for these tests (Milliken and Johnson 1984) where P values are the significance levels given in Table 3 , and the P' values are the significance levels given by Student's t test.
Values in the text are means Â±so.
RESULTS AMD DISCUSSION
Food consumption. The use of alkaloid-supple mented diets requires estimation of food consumption to approximate dose ranges and select doses (Dugan et al. 1989) . In a previous study, Friedman (1992) used estimated food consumption (in terms of daily food intake and intake per kg mouse) to gauge the possible dose ranges for weanling male mice fed various levels of solasodine. Daily food intakes (g/d) of mice exposed to the high dose (0.16% or 3.8 mmol/kg diet) for 7 d was significantly below controls (3.2 vs. 2.8 g/d). How ever, food intake relative to body weight did not differ [214 vs. 216 g/(kg mouse x d)] because the experimental mice did not gain as much weight as the controls. Thus, in that study, food consumption appeared to be incon sequential for estimation of dose range.
In our current study with adult female mice, daily food intake was significantly below controls in the sola sodine group treated with 4.8 mmol/kg diet for 7 d (5.2 Â±0.5 vs. 6.0 Â±0.5 g/d, P s 0.001) and the solanidine group treated with 4.8 mmol/kg diet for 14 d (4.9 Â±0.5 vs. 6.2 Â±0.7 g/d, P s 0.001). Food intake per kilogram body weight was significantly below controls in the so lasodine group treated with 4.8 mmol/kg diet for 7 d [190 Â±15 vs. 216 Table 2 for data on solasodine, tomatidine, and solanidine and Table 3 for data on DHEA). Thus, we selected the 28-d exposure period for comparison of liver weight increases without significant differences in estimated food consumption in studies involving the aglycones.
Changes in body weight. The %LW/BW could vary based on changes in either variable. It was therefore necessary to define conditions in which differences in %LW/BW were due to liver weight gain only. We also used body weight loss as a means of assessing relative toxicity of the alkaloids tested because loss of body weight is perhaps one of the best indicators of toxicity Gumbmann 1984, 1988) . In the study mentioned above (Friedman 1992) , dif ferences in body weight from controls were due to lower body weight gains in weanling mice fed solaso dine diets for 14 d. Friedman found significantly lower body weight gains [P =s 0.01) in weanling mice fed 0.08% (1.9 mmol/kg diet) and 0.16% (3.8 mmol/kg diet) solasodine diets when compared with controls. The present study used 8-wk-old adult female mice. Thus, we were concerned with absolute decreases in overall body weight. Significant decreases relative to controls were observed for the solanidine groups treated with 2.4 mmol/kg diet for 7 d (-2.7 Â±1.5 vs. 0.4 Â±1.5 g, P =s 0.001) and with 4.8 mmol/kg diet for 14 d (-4.3 Â± 1.1 vs.-O.l Â±1.1 g, P =s0.001). Significant body weight losses were also observed in 7-d studies with the glycoalkaloids a-chaconine and a-solanine. The relative magnitudes of body weight losses could be assessed based on percentage body weight differences relative to an average initial body weight and on the following P values for body weight differences relative to controls from the two-tailed Dunnett's tests: a-chaconine (-12.0%, P =s 0.001), a-solanine (-6.5%, P^0.001), solanidine (-10.0%, P^0.001), solasonine (-3.3%, P A 0.05), a-tomatine (2.1%, NS), solasodine (-0.7%, NS) and tomatidine (-0.1%, NS) (values for %BW differ ence vs. average initial body weight are derived from data not shown and P values for body weight differ ences are from Tables 1 and 2 ). Body weight differences vs. controls were not significant in groups treated with the aglycones or DHEA for 28 d (Tables 2 and 4) . Thus, differences in %LW/BW in these groups were due only to increased liver weight.
TABLE 3
Effects on relative liver weight in mice fed a solasodine or solanidine diet followed by a control diet or a control diet followed by a solasodine or solanidine diet for 14 d each1-2 Glycoalkaloids. Mice were fed a-chaconine, a-sola nine, a-tomatine and solasonine for 7 d at 2.4 mrnol/ kg diet. The 7-d exposure with the 2.4 mmol/kg diet was selected for experiments with the glycoalkaloids because mice treated with a-chaconine and a-solanine responded with decreased body and liver weights, and the glycoalkaloids were not available in sufficient quantity for longer studies. Because both body and liver weights decreased relative to controls in these mice, we were interested only in the difference in %LW/BW which was significant (P Ã"0.05) for a-chaconine but not for the other glycoalkaloids (Table 1) . This lower %LW/BW was in contrast to the %LW/BW observed with the corresponding aglycone, solanidine, which was higher than controls under comparable dietary conditions (see Fig. 2 for contrast) . The %LW/BW was not significantly different than controls in mice treated with the eggplant glycoalkaloid, solasonine, whereas a higher %LW/BW was observed with its corresponding aglycone, solasodine. Significant differences in %LW/ BWs were not observed for the tomato glycoalkaloid, a-tomatine, or its corresponding aglycone, tomatidine. However, an increased %LW/BW (P s 0.001) was ob served in mice fed a higher dose for 7 d with tomatidine (4.8 mmol/kg diet, Table 2 ).
The significantly lower liver weights of mice treated with a-chaconine (P =s0.05) and a-solanine (P Ã"0.05) and the significantly lower %LW/BW of mice treated with a-chaconine (P & 0.05) suggest that these effects may be due to hepatotoxicity. Previously, Dalvi (1985) and Dalvi and Jones (1986) found higher activities of serum glutamate-oxaloacetate transaminase and serum glutamate-pyruvate transaminase as well as lower ac tivities of serum cholinesterase and microsomal en zymes in rats injected intraperitoneally with 20 mg/kg of a-solanine when compared with controls. Differ- . The measure ment of these hepatic marker enzymes is an obvious next step for future work with glycoalkaloid diets.
Aglycones and DHEA. In a previous study, the ad ministration of 0.16% (3.8 mmol/kg diet) solasodine in the diet for 14 d led to a significant 64% increase in %LW/BW in male weanling mice (calculated from data in Friedman 1992). We chose adult female mice for this study for the following reasons: Ã•) we wanted to test for differences in liver weight under conditions in which food consumption and body weight were not different than controls to determine whether the test compounds can increase liver weight without affecting body weight; and 2) we wanted data that would help us in dose and time selection for subsequent studies with pregnant mice. The objectives of these follow-up studies with dietary aglycones involved further obser vations on dose response, time course and possible re versibility in terms of differences in liver weights.
The dietary treatment of female mice for only 7 d with 2.4 mmol/kg diet of the eggplant aglycone, solasodine, led to significant increases in liver weight (P & 0.01) and %LW/BW (P^0.01) without significant differences in body weight and food consumption (Table 2 ). In the high est dose (4.8 mmol/kg diet), we observed a 45% increase in %LW/BW (calculated from data in Table 2 ). However, estimated food consumption was significantly lower than that of controls in this group. The %LW/BW was on the order of 8% higher than controls in the group treated with 2.4 mmol/kg diet for 7 d without significant changes in estimated food consumption or body weight. In ani mals treated for 14 d, %LW/BW gains on the order of 57 and 28% were observed in the 4.8 and 2.4 mmol/kg diet groups, respectively, without significant differences in estimated food consumption or body weight (calculated from data in Table 2 ). These values were sustained for mice treated for 28 d in both the 4.8 mmol/kg diet dose (60%, calculated from data in Table 2 ) and the 2.4 mmol/ kg diet dose (22%, Fig. 3 ). When mice were treated with a solasodine-containing diet followed by a solasodine-free diet for 14 d each, liver weights and %LW/BW returned to near control values (Table 3 , Fig. 4 ). This indicates a reversible effect on the mouse liver rather than perma nent damage. Changing the sequence, i.e., feeding a con trol diet for 14 d followed by a solasodine-containing diet for another 14 d, resulted in liver weight and %LW/BW gains comparable to treatments in the first 14-d exposure period (Table 3 , Fig. 4) .
Although solasodine and tomatidine are structurally similar, the dietary treatment of female mice with to matidine led to %LW/BW increases which were~one third of those found with solasodine (e.g., gains in mice fed the 2.4 mmol/kg diet for solasodine and tomatidine were 22 vs. 6%, respectively, for the 28-d exposure pe riod) (Fig. 3) .
The dietary treatment of female mice with solanidine for 7, 14 and 28 d led to LW/BW increases of 27%, 19% and 32%, respectively, in the 2.4 mmol/kg diet groups (7-and 14-d values calculated from data in Table  2 ; 28-d value, see Fig. 3 ). The %LW/BW increases were comparable to those observed in the solasodine group treated with 2.4 mmol/kg diet for 28 d in which body weight differences were not significantly different than controls i.e., solanidine, 32% (P < 0.001 )vs. solasodine, 22% (P s 0.001) (Fig. 3) . As with solasodine, the ob served solanidine-induced hepatomegaly was revers ible (Fig. 4) . We also observed increased % LW/BW (16%, P < 0.001 ) in mice treated with the natural adre nal steroid, DHEA, at the 2.4 mmol/kg diet dose for 28 d (calculated from the data in Table 4 ).
Based on conditions in which there were no signifi cant differences in body weight and food consumption, i.e., 2.4 mmol/kg doses for 28 d, we evaluated the relative potency of the aglycones and DHEA with regard to %LW/BW difference vs. controls (Fig. 3) and %LW/BW gains in mice based on P values from the one-tailed Dunnett's test (Tables 2, 4 ). The results were as follows: solanidine (32%, P Ã"0.001),solasodine (22%, P =s0.001), DHEA (16%, P s 0.001) and tomatidine (6%, NS).
Structure/biological activity relationships. Solani dine, solasodine and DHEA are structurally similar in that they share identical A-D rings of the steroid (Fig.  1) . Solanidine and solasodine differ in the E-and Frings. Solasodine's E-ring is an oxygen heterocycle and the F-ring is a nitrogen heterocycle, whereas solanidine has fused nitrogenous E-and F-rings. In spite of these structural differences, solanidine and solasodine appear to have similar effects on liver weight and %LW/BW in terms of potency and reversibility. DHEA, which also induces hepatomegaly (Table 4) , lacks the E-and F-rings entirely. Thus, structural differences in the Eand F-rings apparently have little effect on the observed hepatomegaly.
Solasodine and tomatidine are structurally similar. The only differences between them are that Ã• ) tomati- Table 3 for results of statistical tests. Abbreviations: trt/cntl = treated (aglycone-containing) diet followed by control diet; cntl/trt = control diet followed by treatment diet. dine lacks the double bond in the 5,6 position of the B-ring and 2) the 25-methyl group in the nitrogenous Fring is epimeric. Because solasodine induces significant hepatomegaly and tomatidine does not, and because structural differences in the F-ring appear to have little effect, we conclude that the 5,6 double bond is likely responsible for the observed differences in potency in inducing liver enlargement.
Although we do not have specific evidence to ex plain the underlying mechanism for the observed liver enlargement, Beilei et al. (1992) suggest that the hepa tomegaly induced by DHEA in rat livers may be due to a dramatic increase in the size and number of hepatocyte peroxisomes. The activities of the peroxisomal marker enzymes catalase and fatty acyl-CoA oxidase also increase significantly. The study of these enzymes is an obvious next step for future work with solanidine and solasodine.
As previously mentioned, the difference in biologi cal effect of glycosylating the 3-OH group of the agly cones is profound. Instead of causing liver enlargement, feeding mice the glycosides either has little effect or may cause liver weight loss. The most likely explana tion for this is that glycosylation radically alters solu bility and polarity by adding a hydrophilic component to an essentially hydrophobic molecule (Friedman and McDonald 1995) . Although the nitrogen atoms of aglycones and glycoalkaloids can participate in acid-base equilibria, the aglycones are more hydrophobic (less water-soluble and more fat-soluble) than the glycoalka loids which have both hydrophobic and hydrophilic character. These differences could influence interac tions with other dietary constituents in vitro and in vivo, metabolism by gut bacterial enzymes, absorption from the digestive tract, transport to target organs, binding to receptor sites, disruption of cell membranes, induction of liver enzymes, residence time in the liver, or histopathology, as discussed in more detail else where (Blankemeyer et al. 1992 , Caldwell et al. 1991 , Dalvi and Jones 1986 , Friedman 1992 , Fried man and Henika 1992 , Rayburn et al. 1994 . Additional studies are required to better define these possibilities.
Dietary consumption of solanaceous steroidal aglycones, but not the glycoalkaloids, results in increases in mouse liver weights. Of the three aglycones studied, we were most interested in solanidine for the following reasons: Ã• ) it may be formed in vivo via either acid or enzymatic hydrolysis from the potato glycoalkaloids a-chaconine or a-solanine; 2} it may be absorbed and/ or persist in tissues after hydrolysis (Alozie et al. 1979 , Ciaringbold et al. 1982 , Harvey et al. 1985a and 1985b , Hellenas et al. 1992b ; and 3) it may accumulate in transgenic potatoes in which the enzymes for glycoalkaloid synthesis are suppressed (Stapleton et al. 1991) .
We also found that the hepatomegaly induced by solanidine and solasodine apparently is a reversible condition, in that liver weights return to near normal values when the mice are taken off the solanidine diets. Some unanswered questions with regard to solanidine include: 1) Does the solanidine-induced hepatomegaly involve hepatocyte peroxisomal proliferation?; 2) Do other species vary in susceptibility to this hepatomeg aly?; 3) Is solanidine an antif ertility agent like solaso dine (Dixit et al. 1989) ?; and 4} Does the consumption by mice fed 5-7 mg/d of solanidine have any relevance to humans whose weight (about 60 kg) is~2000 times that of a mouse?
Some evidence suggests that solanidine may not ad versely affect human health. This evidence includes the following: 1) the high dose required for hepatomeg aly in mice,-2) our earlier observations that solanidine does not appear to be embryotoxic or teratogenic to frog embryos 1992) ; 3) the finding that oral administration via gavage did not in duce omithine decarboxylase in rats (Caldwell et al. 1991) ; and 4} our observation that the hepatomegaly induced by solanidine is reversible (Table 3, Fig. 4 ).
This suggests that the aglycone-induced liver enlarge ment may be an adaptive response.
The two other aglycones, tomatidine and solasodine, also appear to be relatively benign in terms of hepato megaly. Solasodine was comparable in potency to so lanidine, and tomatidine had only one third the po tency of solanidine. However, there is some concern that increased human exposure to solasodine may oc cur because of its proposed use as an antifertility drug. This study raises several questions which merit fur ther study. These include the following: Ã•)What is the species-dependence and mechanism of the cited changes in liver weights?; 2) Can some of the test com pounds act synergistically? (Fewell et al. 1994 , Rayburn et al. 1995b ); 3) Can dietary constituents protect ani mals and humans against adverse effects of glycoalka loids? (Rayburn et al. 1995a ); 4) Can the pharmacokinetics and metabolism of glycoalkaloids and aglycones be defined in humans (Claringbold et al. 1992 , Harvey et al. 1985a and 1985b , Hellenas et al. 1992b ?; and 5) Can intravenous infusion studies (Hellenas et al. 1992a ) predict adverse effects of glycoalkaloids con sumed orally?
A critical assessment of some of these issues (Hop kins 1995) suggests that the status of glycoalkaloids in the human diet is poorly defined and requires further study. Because humans seem to be more sensitive than rodents to the toxicological effects of glycoalkaloids (Morris and Lee 1984) , it is difficult to estimate a hu man "margin of safety" based on our studies in mice without answers to some of these questions.
Finally, since DHEA is reported to exhibit anti-carcinogenesis (Schwartz and Pashko 1993) , and solasonine is effective against malignant skin lesions (Cham et al. 1991) , possibly by inhibiting sodium ion active trans port across and disruption of cell membranes (Blanke meyer et al. 1995) , it may also be worthwhile to investi gate in detail the anti-carcinogenic and anti-viral (Thome et al. 1985) potential of the steroidal aglycones and glycoalkaloids.
